List of Tables
    Table 1. Metastatic Melanoma Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Metastatic Melanoma Drug Market Trends
    Table 3. Metastatic Melanoma Drug Market Drivers
    Table 4. Metastatic Melanoma Drug Market Challenges
    Table 5. Metastatic Melanoma Drug Market Restraints
    Table 6. Global Metastatic Melanoma Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Metastatic Melanoma Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Metastatic Melanoma Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Metastatic Melanoma Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Metastatic Melanoma Drug Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Metastatic Melanoma Drug Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Metastatic Melanoma Drug Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Metastatic Melanoma Drug Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Metastatic Melanoma Drug Sales Share by Manufacturer, 2017-2022
    Table 15. Global Metastatic Melanoma Drug Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Metastatic Melanoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Drug as of 2021)
    Table 18. Top Players of Metastatic Melanoma Drug in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Metastatic Melanoma Drug Product Type
    Table 20. Date of International Manufacturers Enter into Metastatic Melanoma Drug Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Metastatic Melanoma Drug Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Metastatic Melanoma Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Metastatic Melanoma Drug Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Metastatic Melanoma Drug Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Metastatic Melanoma Drug Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Metastatic Melanoma Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Metastatic Melanoma Drug Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Metastatic Melanoma Drug Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Metastatic Melanoma Drug Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Metastatic Melanoma Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Metastatic Melanoma Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Metastatic Melanoma Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Metastatic Melanoma Drug Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Metastatic Melanoma Drug Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Metastatic Melanoma Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Metastatic Melanoma Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Metastatic Melanoma Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Metastatic Melanoma Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Metastatic Melanoma Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Metastatic Melanoma Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Merck & Co., Inc. Corporation Information
    Table 43. Merck & Co., Inc. Description and Business Overview
    Table 44. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Merck & Co., Inc. Metastatic Melanoma Drug Product
    Table 46. Merck & Co., Inc. Recent Development
    Table 47. Merck KGaA Corporation Information
    Table 48. Merck KGaA Description and Business Overview
    Table 49. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. Merck KGaA Product
    Table 51. Merck KGaA Recent Development
    Table 52. Millennium Pharmaceuticals, Inc. Corporation Information
    Table 53. Millennium Pharmaceuticals, Inc. Description and Business Overview
    Table 54. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. Millennium Pharmaceuticals, Inc. Product
    Table 56. Millennium Pharmaceuticals, Inc. Recent Development
    Table 57. Morphotek, Inc. Corporation Information
    Table 58. Morphotek, Inc. Description and Business Overview
    Table 59. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Morphotek, Inc. Product
    Table 61. Morphotek, Inc. Recent Development
    Table 62. NewLink Genetics Corporation Corporation Information
    Table 63. NewLink Genetics Corporation Description and Business Overview
    Table 64. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. NewLink Genetics Corporation Product
    Table 66. NewLink Genetics Corporation Recent Development
    Table 67. Novartis AG Corporation Information
    Table 68. Novartis AG Description and Business Overview
    Table 69. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Novartis AG Product
    Table 71. Novartis AG Recent Development
    Table 72. Omeros Corporation Corporation Information
    Table 73. Omeros Corporation Description and Business Overview
    Table 74. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Omeros Corporation Product
    Table 76. Omeros Corporation Recent Development
    Table 77. Oncolytics Biotech Inc. Corporation Information
    Table 78. Oncolytics Biotech Inc. Description and Business Overview
    Table 79. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Oncolytics Biotech Inc. Product
    Table 81. Oncolytics Biotech Inc. Recent Development
    Table 82. OncoSec Medical Inc. Corporation Information
    Table 83. OncoSec Medical Inc. Description and Business Overview
    Table 84. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. OncoSec Medical Inc. Product
    Table 86. OncoSec Medical Inc. Recent Development
    Table 87. Ono Pharmaceutical Co., Ltd. Corporation Information
    Table 88. Ono Pharmaceutical Co., Ltd. Description and Business Overview
    Table 89. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Ono Pharmaceutical Co., Ltd. Product
    Table 91. Ono Pharmaceutical Co., Ltd. Recent Development
    Table 92. Pfizer Inc. Corporation Information
    Table 93. Pfizer Inc. Description and Business Overview
    Table 94. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Pfizer Inc. Product
    Table 96. Pfizer Inc. Recent Development
    Table 97. Pharmis Biofarmaceutica, Lda. Corporation Information
    Table 98. Pharmis Biofarmaceutica, Lda. Description and Business Overview
    Table 99. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Pharmis Biofarmaceutica, Lda. Product
    Table 101. Pharmis Biofarmaceutica, Lda. Recent Development
    Table 102. Philogen S.p.A. Corporation Information
    Table 103. Philogen S.p.A. Description and Business Overview
    Table 104. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Philogen S.p.A. Product
    Table 106. Philogen S.p.A. Recent Development
    Table 107. Plexxikon Inc. Corporation Information
    Table 108. Plexxikon Inc. Description and Business Overview
    Table 109. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Plexxikon Inc. Product
    Table 111. Plexxikon Inc. Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. Metastatic Melanoma Drug Customers List
    Table 115. Metastatic Melanoma Drug Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. Metastatic Melanoma Drug Product Picture
    Figure 2. Global Metastatic Melanoma Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Metastatic Melanoma Drug Market Size 2017-2028 (US$ Million)
    Figure 4. Global Metastatic Melanoma Drug Sales 2017-2028 (K Pcs)
    Figure 5. United States Metastatic Melanoma Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Metastatic Melanoma Drug Market Size 2017-2028 (US$ Million)
    Figure 7. United States Metastatic Melanoma Drug Sales 2017-2028 (K Pcs)
    Figure 8. United States Metastatic Melanoma Drug Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Metastatic Melanoma Drug Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Metastatic Melanoma Drug Report Years Considered
    Figure 11. Product Picture of AGI-134
    Figure 12. Product Picture of ALT-801
    Figure 13. Product Picture of ALT-803
    Figure 14. Product Picture of AMG-232
    Figure 15. Product Picture of Others
    Figure 16. Global Metastatic Melanoma Drug Market Share by Type in 2022 & 2028
    Figure 17. Global Metastatic Melanoma Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Metastatic Melanoma Drug Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Metastatic Melanoma Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 20. Global Metastatic Melanoma Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Metastatic Melanoma Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 22. United States Metastatic Melanoma Drug Market Share by Type in 2022 & 2028
    Figure 23. United States Metastatic Melanoma Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Metastatic Melanoma Drug Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Metastatic Melanoma Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 26. United States Metastatic Melanoma Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Metastatic Melanoma Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 28. Product Picture of Hospital
    Figure 29. Product Picture of Clinic
    Figure 30. Product Picture of Others
    Figure 31. Global Metastatic Melanoma Drug Market Share by Application in 2022 & 2028
    Figure 32. Global Metastatic Melanoma Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 33. Global Metastatic Melanoma Drug Sales Market Share in Value by Application (2017-2028)
    Figure 34. Global Metastatic Melanoma Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 35. Global Metastatic Melanoma Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 36. Global Metastatic Melanoma Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 37. United States Metastatic Melanoma Drug Market Share by Application in 2022 & 2028
    Figure 38. United States Metastatic Melanoma Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 39. United States Metastatic Melanoma Drug Sales Market Share in Value by Application (2017-2028)
    Figure 40. United States Metastatic Melanoma Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 41. United States Metastatic Melanoma Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 42. United States Metastatic Melanoma Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 43. North America Metastatic Melanoma Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 44. North America Metastatic Melanoma Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 45. U.S. Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Canada Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Europe Metastatic Melanoma Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 48. Europe Metastatic Melanoma Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 49. Germany Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. France Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. U.K. Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Italy Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Russia Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Asia-Pacific Metastatic Melanoma Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 55. Asia-Pacific Metastatic Melanoma Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 56. China Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Japan Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. South Korea Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. India Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Australia Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Taiwan Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Indonesia Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Thailand Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Malaysia Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Philippines Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Latin America Metastatic Melanoma Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 67. Latin America Metastatic Melanoma Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 68. Mexico Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Brazil Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Argentina Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Middle East & Africa Metastatic Melanoma Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 72. Middle East & Africa Metastatic Melanoma Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 73. Turkey Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Saudi Arabia Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. U.A.E Metastatic Melanoma Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Metastatic Melanoma Drug Value Chain
    Figure 77. Metastatic Melanoma Drug Production Process
    Figure 78. Channels of Distribution
    Figure 79. Distributors Profiles
    Figure 80. Bottom-up and Top-down Approaches for This Report
    Figure 81. Data Triangulation
    Figure 82. Key Executives Interviewed